- CH₣3.52bn
- CH₣4.18bn
- CH₣3.75bn
- 86
- 39
- 65
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.68 | ||
| PEG Ratio (f) | 3.09 | ||
| EPS Growth (f) | 6.8% | ||
| Dividend Yield (f) | 3.27% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.39 | ||
| Price to Tang. Book | 8.96 | ||
| Price to Free Cashflow | 23.58 | ||
| Price to Sales | 0.94 | ||
| EV to EBITDA | 14.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.98% | ||
| Return on Equity | 12.14% | ||
| Operating Margin | 5.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 3,301 | 3,479.75 | 3,834.68 | 3,588.46 | 3,746.01 | 3,918.12 | 4,070.11 | 3.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -15.7 | +39.15 | -8.54 | -2.95 | +5.33 | +7.11 | +6.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Directors
- Daniela Bosshardt-Hengartner NEC (48)
- Marc Werner CEO (54)
- Bertrand Jungo NVC (55)
- Felix Burkhard CFO (54)
- Virginie Jeschka EXB (42)
- Andreas Koch EXB (50)
- Daniele Madonna EXB (43)
- Thomas Szuran EXB (53)
- Barbara Walchli SEC
- Pascale Bruderer IND (44)
- Michel Burnier IND (67)
- Markus Neuhaus IND (63)
- Philippe Nussbaumer IND (51)
- Andreas Walde IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 13th, 2017
- Public Since
- April 7th, 2017
- No. of Employees
- 5,907
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
SIX Swiss Exchange- Shares in Issue
- 49,832,180
- Address
- Untermattweg 8, BERN, 3027
- Web
- https://www.galenica.com/
- Phone
- Auditors
- Ernst & Young Ltd
Latest News for GALE
Upcoming Events for GALE
Half Year 2024 Galenica AG Earnings Release
Similar to GALE
Cosmo Pharmaceuticals NV
SIX Swiss Exchange
Dottikon Es Holding AG
SIX Swiss Exchange
Newron Pharmaceuticals SpA
SIX Swiss Exchange
Novartis AG
SIX Swiss Exchange
PolyPeptide AG
SIX Swiss Exchange
FAQ
As of Today at 19:08 UTC, shares in Galenica AG are trading at CH₣70.65. This share price information is delayed by 15 minutes.
Shares in Galenica AG last closed at CH₣70.65 and the price had moved by -9.89% over the past 365 days. In terms of relative price strength the Galenica AG share price has underperformed the FTSE Global All Cap Index by -16.88% over the past year.
The overall consensus recommendation for Galenica AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Galenica AG dividend yield is 3.11% based on the trailing twelve month period.
Last year, Galenica AG paid a total dividend of CH₣2.20, and it currently has a trailing dividend yield of 3.11%.Looking ahead, the next dividend pay date is 2024-04-16.
We do not have data on when Galenica AG is to next pay dividends. The historic dividend yield on Galenica AG shares is currently 3.11%.
To buy shares in Galenica AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣70.65, shares in Galenica AG had a market capitalisation of CH₣3.52bn.
Here are the trading details for Galenica AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: GALE
Based on an overall assessment of its quality, value and momentum Galenica AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Galenica AG is CH₣76.50. That is 8.28% above the last closing price of CH₣70.65.
Analysts covering Galenica AG currently have a consensus Earnings Per Share (EPS) forecast of CH₣3.53 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galenica AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -6.09%.
As of the last closing price of CH₣70.65, shares in Galenica AG were trading -1.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Galenica AG PE ratio based on its reported earnings over the past 12 months is 19.68. The shares last closed at CH₣70.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Galenica AG's management team is headed by:
- Daniela Bosshardt-Hengartner - NEC
- Marc Werner - CEO
- Bertrand Jungo - NVC
- Felix Burkhard - CFO
- Virginie Jeschka - EXB
- Andreas Koch - EXB
- Daniele Madonna - EXB
- Thomas Szuran - EXB
- Barbara Walchli - SEC
- Pascale Bruderer - IND
- Michel Burnier - IND
- Markus Neuhaus - IND
- Philippe Nussbaumer - IND
- Andreas Walde - IND